MABPHARM-B (02181): Dr. Zhang Yanyun Appointed as Lead Independent Non-Executive Director
Stock News
Oct 31
Effective October 31, 2025, MABPHARM-B (02181) announced the following changes: Dr. Qian Weizhu, an executive director, has been appointed as a member of the company's nomination committee. Mr. Tao Jing, also an executive director, has stepped down from his role on the nomination committee. Additionally, Dr. Zhang Yanyun, currently serving as an independent non-executive director, chair of the remuneration committee, and member of the nomination committee, has been designated as the lead independent non-executive director.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.